Molina Healthcare reported first‑quarter 2026 results that included an adjusted earnings per share of $2.35, a $0.56 to $0.78 beat over the consensus range of $1.79 to $2.17. Revenue was $10.2 billion to $10.8 billion, slightly below the $10.83 billion to $10.87 billion estimate, and 4 % lower year‑over‑year. The company’s GAAP net income per diluted share fell to $0.27 from $5.45 a year earlier, while adjusted net income per diluted share dropped to $2.35 from $6.08 a year earlier.
The adjusted EPS beat was driven by disciplined medical‑cost management and a modestly favorable medical‑cost trend. Molina’s medical cost ratio (MCR) improved to 91.1 % from 89.2 % year‑over‑year, and the adjusted pre‑tax margin fell to 1.6 % from 3.9 % a year earlier, reflecting tighter cost control amid a 4 % revenue decline. The company also recorded a $93 million impairment charge related to the planned exit of its Medicare Advantage‑Part D product for 2027, which helped offset the revenue shortfall.
Revenue fell 4 % year‑over‑year because Medicaid and Marketplace membership declined. Medicaid attrition was revised upward to a 6 % decline from the previously expected 2 %, and a Medicaid contract in Virginia expired. Marketplace membership also slipped, and the exit of the Medicare Advantage‑Part D product removed a revenue source. Segment‑level data show Medicaid MCR at 92.0 % and Medicare MCR at 89.8 %, while the Marketplace MCR was 84.0 % (adjusted to 79.5 % after accounting for prior‑year risk adjustment).
Molina reaffirmed its full‑year 2026 guidance, projecting premium revenue of approximately $42 billion and adjusted EPS of at least $5.00. The guidance reflects a cautious outlook that balances the company’s disciplined cost management with the headwinds of membership attrition and a challenging cost environment. CEO Joseph Zubretsky said, "We are pleased with our first quarter results and continued disciplined approach to medical cost management," and added, "Medical cost trend was modestly favorable to our expectations, and our reaffirmed full year 2026 premium revenue and adjusted earnings guidance reflect a prudent view of full year results at this early point in the year."
The earnings beat and guidance reaffirmation signal that Molina is managing costs effectively while navigating a complex mix of regulatory and membership headwinds. The company’s focus on strategic product transitions—particularly the exit of Medicare Advantage‑Part D and the integration of Medicare‑Medicaid plan members—positions it for future growth, even as it faces a trough in Medicaid industry margins. The results underscore the importance of disciplined cost control and strategic portfolio management in a highly regulated health‑insurance market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.